Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 4.01
- Piotroski Score 7.00
- Grade Buy
- Symbol (MRK)
- Company Merck & Co., Inc.
- Price $97.87
- Changes Percentage (0.44%)
- Change $0.43
- Day Low $96.95
- Day High $98.43
- Year High $134.63
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 12/16/2024
- Dividend Payable 01/08/2025
- Today N/A
- Next Earnings (Estimated) 02/04/2025
- Fiscal Year End N/A
- Average Stock Price Target $132.00
- High Stock Price Target $294.00
- Low Stock Price Target $80.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.91
- Trailing P/E Ratio 143.59
- Forward P/E Ratio 143.59
- P/E Growth 143.59
- Net Income $365.00 M
Income Statement
Quarterly
Annual
Latest News of MRK
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Merck & Co., Inc. (MRK)'s Blockbuster Drugs: A Key Player in Ken Griffin's Portfolio
We recently featured Ken Griffin's stock portfolio, highlighting Merck & Co., Inc. against other stocks. Griffin's success with Citadel Investment Group, boasting a $518 billion portfolio, includes Ci...
By Yahoo! Finance | 20 hours ago -
Jim Cramer Says Merck & Co., Inc. (MRK) Is 'Just Way Too Hated'
Jim Cramer discussed the market's extreme volatility post-election, highlighting sectors with significant gains and losses. He noted industries thriving for specific reasons and cautioned investors to...
By Yahoo! Finance | 2 days ago -
Statutory Profit Doesn't Reflect How Good Newmark Group's (NASDAQ:NMRK) Earnings Are
Newmark Group, Inc.'s positive earnings report led to a stock price increase. Despite unusual expenses, the company is expected to improve profits next year. Analysts predict future profitability, and...
By Yahoo! Finance | 5 days ago
